This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Clinical Performance Comparison of Two Contact Lenses

This study has been completed.
Sponsor:
Collaborator:
Visioncare Research Ltd.
Information provided by (Responsible Party):
Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier:
NCT00975585
First received: September 10, 2009
Last updated: May 5, 2015
Last verified: May 2015
September 10, 2009
May 5, 2015
August 2009
October 2009   (Final data collection date for primary outcome measure)
  • Average Corneal Staining [ Time Frame: 2 weeks ]
    The overall score is the average of the total scores of each of five regions of the cornea. The minimum average score is 0 and the maximum average score is 3. Corneal surface abnormality as indicated by the severity of staining over five regions of the cornea (central, superior, inferior, nasal and temporal) was assessed by the investigator using the following scale: 0=none, 1=slight, 2=moderate, 3=severe.
  • Visual Acuity [ Time Frame: 2 weeks ]
    Visual acuity was assessed by the investigator using the Snellen chart and converted to the logarithm of the minimum angle of resolution (logMAR). logMAR ideal is 0.0 and represents 20/20 Snellen visual acuity. logMAR values > 0.00 indicate vision poorer than the ideal and values <0.00 indicate vision greater than the ideal.
  • Overall Comfort [ Time Frame: 2 weeks ]
    After two weeks of wear, subjects responded to a phone survey question regarding overall comfort of the study contact lenses (senofilcon A and lotrafilcon B) using the following scale: 5=excellent, 4=very good, 3=good, 2=fair, 1=poor.
  • Overall Comfort [ Time Frame: 2 weeks and 4 weeks ]
    After four weeks of wear, subjects responded to a phone survey question regarding overall comfort of the study contact lenses (lotrafilcon B)using the following scale: 5=excellent, 4=very good, 3=good, 2=fair, 1=poor.
  • corneal staining [ Time Frame: every 2 weeks ]
  • visual acuity [ Time Frame: every 2 weeks ]
  • subjective comfort ratings [ Time Frame: every 2 weeks ]
Complete list of historical versions of study NCT00975585 on ClinicalTrials.gov Archive Site
  • Limbal Redness [ Time Frame: 2 weeks ]
    The investigator assessed limbal redness using the following scale: 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe
  • Bulbar Redness [ Time Frame: 2 weeks ]
    The investigator assessed bulbar redness using the following scale: 0=None, 1=Trace, 2=Mild, 3=Moderate, 4=Severe
  • Symptoms of Dryness [ Time Frame: 2 weeks ]
    Subjects responded to a phone survey question regarding the frequency of the sensation of dryness while wearing the study contact lenses using the following scale: 1=Extreme, 2=Moderate, 3=Slight, 4=None
limbal and bulbar redness [ Time Frame: every 2 weeks ]
Not Provided
Not Provided
 
Clinical Performance Comparison of Two Contact Lenses
Clinical Evaluation of Two Silicone Hydrogel Frequent Replacement Contact Lenses
The purpose of this study is to compare the clinical performance of two contact lenses.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Myopia
  • Device: senofilcon A
    soft contact lens, 2-week replacement indicated
  • Device: lotrafilcon B
    soft contact lens with a 4-week replacement indicated.
  • Active Comparator: senofilcon A both eyes
    soft contact lens worn daily for 2 weeks, with a 2-week replacement regimen.
    Intervention: Device: senofilcon A
  • Active Comparator: lotrafilcon B both eyes
    soft contact lens worn daily for 4 weeks, with a 4-week replacement regimen
    Intervention: Device: lotrafilcon B
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
379
Not Provided
October 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Existing daily soft lens wearer.
  • Require a distance visual correction in both eyes.
  • Have a contact lens spherical distance refraction between -1.00D and -6.00D.
  • Have refractive astigmatism less than or equal to 1.00D in both eyes.
  • Achieve 20/30 or better corrected distance acuity.
  • Have normal eyes with no evidence of abnormality or disease.

Exclusion Criteria:

  • Requires presbyopic correction.
  • Requires ocular medications.
  • Grade 3 or 4 ocular abnormalities.
  • Grade 3 corneal staining in more than one region.
  • Has had refractive surgery.
  • Any other injury or ocular surgery within 8 weeks prior to study enrollment.
  • Has abnormal lacrimal secretions.
  • Pre-existing ocular irritation that would preclude contact lens fitting.
  • Has keratoconus or other corneal irregularity.
  • Polymethyl methacrylate (PMMA), Hybrid or Rigid Gas Permeable (RGP) wear in the previous 8 weeks.
  • Wears habitual contact lenses that are toric, multifocal or worn extended wear.
  • Any systemic illness which would contraindicate lens wear or the medical treatment of would affect vision or successful lens wear.
  • Diabetic.
  • Infectious or immunosuppressive disease.
  • History of chronic eye disease (e.g glaucoma or age related macular degeneration).
  • Pregnancy, lactation or planning pregnancy at time of enrollment.
  • Participation in any concurrent clinical trial or in another trial in the last 30 days.
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00975585
CR-0907
PHNX-518
No
Not Provided
Not Provided
Johnson & Johnson Vision Care, Inc.
Johnson & Johnson Vision Care, Inc.
Visioncare Research Ltd.
Study Director: Sheila , B Hickson-Curran, BSc, MCOptom Johnson & Johnson Vision Care, Inc.
Johnson & Johnson Vision Care, Inc.
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP